Overview
- State and company officials opened phase one and began phase two of the Hetero Labs complex in CIVAC this week, describing the development as the start of a long‑term manufacturing commitment in Jiutepec.
- Hetero Labs is investing nearly $50 million through Mexican subsidiaries Amarox Pharma and Camber Pharma, up from an initially planned $40 million for a three‑stage project.
- The plant is planned to produce medicines for HIV/AIDS, diabetes, cardiovascular disease, cancer and a range of biotechnological products, according to company and government statements.
- Officials project up to 300 direct jobs and more than 1,000 indirect positions, and federal regulators from Cofepris and the Economy Secretariat took part in the inauguration, signaling early regulatory engagement.
- Local leaders framed the project as a boost to Morelos’s industrial strategy and a response to heavy medicine import dependence, while no firm commercial start dates or final regulatory clearances have been announced.